在人凝血因子VIII的B结构域与酸性区域3界面改变切割可增强血友病A小鼠基因治疗后的表达
本研究对furin切割位点(hFVIII-Δ3)、a3切割位点(hFVIII-S1657P/D1658E,即SP/DE)及两者联合(hFVIII-Δ3-SP/DE)的重组人凝血因子VIII变体进行体外纯化表征,并在AAV介导的基因治疗后于血友病A小鼠体内评价。三种变体比活性与B结构域缺失(BDD)hFVIII相当;对hFVIII耐受的血友病A小鼠在蛋白攻击或AAV递送后未产生针对hFVIII的免疫应答;AAV递送后hFVIII-Δ3-SP/DE的表达水平较hFVIII-BDD高2至5倍。
要点
- hFVIII-Δ3、hFVIII-SP/DE和hFVIII-Δ3-SP/DE变体的比活性与BDD hFVIII相当。
- 对hFVIII耐受的血友病A小鼠在蛋白攻击或AAV递送后未针对hFVIII产生免疫应答。
- AAV递送后hFVIII-Δ3-SP/DE在血友病A小鼠中的表达水平较hFVIII-BDD高2至5倍。
核心结论
- 新型furin与a3切割位点联合变体hFVIII-Δ3-SP/DE较hFVIII-BDD显著改善分泌;作者认为该变体的这一特征可与其它方法联合以进一步改善因子VIII表达,从而在基于AAV的血友病A基因治疗中取得更优疗效。
研究设计与样本
- 研究对furin切割位点变体hFVIII-Δ3、a3切割位点变体hFVIII-S1657P/D1658E(SP/DE)及联合变体hFVIII-Δ3-SP/DE进行重组纯化,并在体外及AAV介导基因治疗后于血友病A小鼠体内进行生化与功能表征。
主要发现
- 重组hFVIII-Δ3、hFVIII-SP/DE和hFVIII-Δ3-SP/DE变体的比活性均与B结构域缺失(BDD)hFVIII相当。
- 对hFVIII耐受的血友病A小鼠在接受这些变体的蛋白攻击后或经腺相关病毒(AAV)递送后,均未产生针对hFVIII的免疫应答。
- AAV递送后,hFVIII-Δ3-SP/DE在血友病A小鼠中的表达水平较hFVIII-BDD高2至5倍。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Variants of human factor VIII (hFVIII) have been developed to further understand the structure and function of hFVIII and improve gene-based therapeutics. We have previously characterized several hFVIII variants of the furin cleavage site (1645-1648) with improved secretion. We have also identified a second cleavage site in the acidic region 3 (a3) (1657-1658) that becomes the primary hFVIII intracellular cleavage position in the absence of the furin site. We tested a hypothesis that modification of this site may confer additional functional advantages to hFVIII. OBJECTIVES: The aim of this study was to conduct the biochemical and functional characterization of hFVIII variants of the furin cleavage site, the a3 cleavage site, or in combination, both in vitro and in vivo after AAV mediated gene therapy. METHODS: Recombinant hFVIII variants of the furin cleavage site (hFVIII-Δ3), the a3 cleavage site (hFVIII-S1657P/D1658E [SP/DE]), or in combination (hFVIII-Δ3-SP/DE) were purified and characterized in vitro and in vivo. RESULTS: Recombinant hFVIII-Δ3, hFVIII-SP/DE, and hFVIII-Δ3-SP/DE variants all had comparable specific activity to B-domain deleted (BDD) hFVIII. Hemophilia A mice tolerant to hFVIII did not develop immune responses to hFVIII after protein challenge with these variants or after adeno-associated virus (AAV) delivery. Following AAV delivery, hFVIII-Δ3-SP/DE resulted in expression levels that were 2- to 5-fold higher than those with hFVIII-BDD in hemophilia A mice. CONCLUSION: The novel hFVIII-Δ3-SP/DE variant of the furin and a3 cleavage sites significantly improved secretion compared with hFVIII-BDD. This key feature of the Δ3-SP/DE variant provides a unique strategy that can be combined with other approaches to further improve factor VIII expression to achieve superior efficacy in AAV-based gene therapy for hemophilia A.
引用
- Nguyen GN, Lindgren JR, Seleme MC, et al. Altered cleavage of human factor VIII at the B-domain and acidic region 3 interface enhances expression after gene therapy in hemophilia A mice. J Thromb Haemost. 2023. PMID: 37080538. doi:10.1016/j.jtha.2023.04.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。